Stein, Sokrates

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation

Nitric Oxide and Endothelin EffectsParaoxonase enzyme and polymorphisms

Cited by 535

Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Gariani, K., Ryu, D., Menzies, K. J., Yi, H.-S., Stein, S., Zhang, H., Perino, A., Lemos, V., Katsyuba, E., Jha, P., et al. (2017) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentSirtuins and Resveratrol in Medicine

Cited by 167

The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression

Miranda, M. X., van Tits, L. J., Lohmann, C., Arsiwala, T., Winnik, S., Tailleux, A., Stein, S., Gomes, A. P., Suri, V., Ellis, J. L., et al. (2015) · European Heart Journal

Cholesterol and Lipid MetabolismSirtuins and Resveratrol in Medicine

Cited by 153